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approached on a one-to-one basis and were requested to participate in the study. A 
previously validated survey instrument that measured awareness, attitude and behavior
towards the wait and watch approach was used. Data were coded and analyzed using
SAS 9.1 to perform descriptive statistics and stepwise multivariate linear regression. 
RESULTS: A total of 89 completed surveys were collected with a response rate of 
22.25%. Majority of the respondents were pediatricians (75%), while 19.32% were 
family practitioners. About 44% of the physicians were aware and familiar with the 
wait and watch approach recommendation from the AAP guideline. In general, physi-
cians had a positive attitude towards the wait and watch approach (3.99 o 0.78). Physi-
cians in this sample reported that they sometimes used the wait and watch approach in
patients q2 years (2.83 o 0.86). Awareness (B  0.256) and attitude (B  0.32) were 
found to be signiﬁ cantly associated with behavior (p  0.05) when controlled for
demographic and decision-making factors in the multivariate regression model. CON-
CLUSIONS: Awareness regarding the wait and watch approach leads to positive atti-
tude that ultimately leads to behavior to use the wait and watch approach. Increased 
use of this approach may reduce antibiotic costs and resistance issues substantially.
Further research on a national sample is needed to validate the study results.
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OBJECTIVES: This paper 1) examines the extent of drug substitution, for example, 
from brand-name drugs to generic drugs and from retail order to mail order; 2) simu-
lates the cost savings associated with drug substitution; and 3) estimates the effects of 
various factors on drug substitution, including patient characteristics, cost sharing and 
generic entry. METHODS: We use pharmacy claims data from three employers for 
working-aged adults and their dependents from 1998 to 2004. We focus on ﬁ ve major
therapeutic classes and track the share of total days supplied of each therapeutic class 
in six categories: generic and retail, multi-source brand and retail, single-source brand 
and retail, generic and mail order, multi-source brand and mail order, single-source
brand and mail order. The shares are compared by drug plan over time and we simu-
late the cost savings (both total costs and OOP costs) by assuming these shares are
ﬁ xed at the 1998 level through the rest of the study period. RESULTS: Per capita drug 
spending is 10%, 12% and 2% lower, respectively, for each plan in 2003 than it would
have been had no substitution occurred since 1998. We ﬁ nd substantial variation in
substitution by therapeutic class, by drug plan and over time. Plan 1 realized the most 
savings from Histamine (H2) Antagonist (185% for Plan 1, 11% for Plan 2 and 45% 
for Plan 3) while Plan 2 realized the most savings from Cardiac, ACE Inhibitors (56%
for Plan 1, 76% for Plan 2 and 23% for Plan 3). Savings on OOP costs vary as well. 
CONCLUSIONS: Drug substitution could result in substantial savings. To more 
effectively promote drug substitution, certain policy steps need to be taken to address 
factors other than cost sharing, such as physician prescribing behaviors.
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OBJECTIVES: To assess health care patterns and patient satisfaction with health care
systems among six European nations. METHODS: TNS European Healthcare Panel 
of individuals in France, Germany, Italy, Spain, UK and the Netherlands were surveyed
in 2007 to assess health care patterns and disease burden at national level. The data
is representative of population gender and age in respective countries, ensured by 
sampling and intensive panel management. The survey collected information on health 
conditions, quality of life, health care-utilization and satisfaction with health care 
system. RESULTS: Approximately 175,000 individuals completed the survey, with 
equal male/female representation. Pain(83,300), Allergy(53,100), Migraine(38,400),
Sleeping problems(35,900), Skin-disease(35,800), Gastrointestinal-disease(34,000), 
Depression(31,200), High blood-pressure(22,800), Urinary-problems(20,200) 
and High-cholesterol(19,200) were the top-10 reported ailments. Across the
countries, 49.9% self-diagnosed a health condition (range: 37.5%(Netherlands)
to 59.5%(Germany)), whereas 13.3% (range: 8.4%(Italy) to 19.1%(Netherlands)) 
and 19.4% (range: 8.8%(UK) to 24.7%(Germany)) reported Primary Care Physician
and Specialist as primary source of diagnosis. Correspondingly, 34.3% (range:
20.1%(Spain) to 59.0%(UK)) reported self-medication, while 26.3% (range:
20.7%(Italy) to 34.1%(France)), 28.8% (range: 8.1%(UK) to 41.2%(France)) and
6.3% (range: 3.8%(Netherlands) to 11.6%(Italy) reported being treated by Primary 
Care Physician/Specialist/Hospital Clinic respectively. Overall, 71.6% (range: 
57.6%(UK) to 82.4%(France)), 36.0% (range: 23.6%(Spain) to 58.5%(UK)), 12.9% 
(range: 3.7%(Netherlands) to 17.7%(France)), 5.4% (range: 2.8%(Netherlands) to
7.5%(UK)) and 9.1% (range: 7.7%(Italy) to 12.3%(UK)) were treated with prescrip-
tion-medications, OTC, plant-based-pharmaceuticals, alternative-therapeutic-options, 
and other products respectively. Satisfaction with health care-system varied dramati-
cally: 49% very-satisﬁ ed/satisﬁ ed (range: 26%(Italy) to 66%(France)); 17% Neutral
(range: 7%(France/Netherlands) to 27%(Italy)) and 34% somewhat/very-dissatisﬁ ed
(range: 27%(France) to 47%(Italy)). CONCLUSIONS: Patient satisfaction with health 
care system appears to be low and reports of self-diagnosis and self-medication are
high in the countries. This highlights the increasing importance of patient involvement 
in health care and treatment and need for integrating patients into health care pro-
cesses in various forms to alleviate health care burden (clinical/economic/humanistic) 
in respective geographies.
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OBJECTIVES: Diagnosis-related Group (DRG) classiﬁ cation as a normative health 
ﬁ nancing system, has been used by the National Health Insurance Fund Administra-
tion (NHIFA) in Hungary since 1993. In the intensive care in our DRG system it can
frequently occur that real cost exceed the reimbursement. In the view of the intensive 
care, the case mix index (CMI) correlate the reimbursement. A 10 years run of the 
CMI was analyzed comparing the global mean CMI of all recognized specialties to
the mean CMI of the intensive therapy. METHODS: Using the data of the NHIFA 
between 1995 and 2005, the CMI of the intensive therapy treatment was compared 
to the mean CMI of all recognized medical specialties. RESULTS: The case-mix index 
of intensive care units increased from 1.69 in 1995 to 4.79 in 2005, while the average 
case-mix index of all medical specialties increased moderately from 1.08 in 1995 to
1.11 in 2005. In the ﬁ rst two years, in 1995 and in 1996, the CMI of the intensive
therapy was 56% more than the global mean. But in 1997, a sudden great increase
happened to 165% and after that to 197% in 1998 and ﬁ nally to 250% in 1999. 
From the year 2000, the rise of CMI was between 1.5% and 22.8% from year to year 
increasing to 333%. During these 10 years, the changing of the global mean CMI of 
the all specialties was only 2.5%. CONCLUSIONS: In Hungary between 1995 and 
2005, while the CMI of all recognized specialties increased only 2.5%, the biggest 
change happened in the intensive specialty. The CMI increased from 1.6 to 4.8 weight-
number which means a 300% rise. During this time, the reimbursement of one 
weight-number runs high too.
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OBJECTIVES: The reimbursement of one patient therapy is always disputed as is 
questioned the exactness of the cost calculation. The goal of our analysis was to deﬁ ne
the change of market share in the reimbursement compared to the change in amount
of patients in intensive therapy in the period between 1995 and 2005 in Hungary.
METHODS: Diagnosis-related Groups (DRG) classiﬁ cation as a normative health
ﬁ nancing system has been used in Hungary since 1993. Data of the analysis was taken 
from the ﬁ nancial database of the Hungarian National Health Insurance Fund Admin-
istration covering the period 1995–2005. RESULTS: In the intensive therapy, the
patient number rate of all in-patient care was 0.75% in 1995. During four years, it
increased slowly. In 1998 it was 0.87%. In 1999 a sudden increase happened, the rate
reached 1.33%, and after that it consistently went up to 1.67% in the last 5 years. 
Comparing 2005 to 1995, the total rise was 123% in number of patients treated in
intensive care units. Using the DRG weight-number as a base value for ﬁ nancing the 
market share, the reimbursement of the intensive therapy was 1.2–1.3% in 1995–
1996, and after that increased to 2.2–2.6% in 1997–1998 and to 4.6% in 1999. From
2000 to 2005 the increase was gradual but progressive. In 2005 the market share of 
the intensive therapy was 7.2%, which (6.2 times more then in 1995). The total change 
was 516%. CONCLUSIONS: While the number of the treated patients increased
123%, the rise of the reimbursement was 516%. So the ﬁ nancing of the intensive 
therapy changed positively between 1995 and 2005 in Hungary.
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OBJECTIVES: The Food and Drug Administration (FDA) regulates prescription drug
marketing, not prescribing, and medication use for non-FDA approved indications 
(“off-label use”) is common. However, many off-label uses lack supporting evidence
and may expose patients to unwarranted risk. We sought to determine physicians’
